You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | -7,882.9% | n/a |
| ROCE | 0.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | -0.8 | 0.0 |
| PEG | 0.0 | -999,999.0 |
| Price / Revenue | 52.5 | 0.0 |
| Price / Book value | 1.2 |
| Latest | Forecast | |
|---|---|---|
| Revenue | -99.6% | 0.0% |
| PBT | 0.0% | n/a |
| EPS | 0.0% | -99.2% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2014-09-30 | n/a | -4.26 | -7.60p | 0.0 | 0.0 | n/a | n/a | 0.0% |
| 2015-09-30 | n/a | -8.82 | -14.10p | -7.2 | 0.0 | n/a | n/a | 0.0% |
| 2016-09-30 | n/a | -15.41 | -19.80p | -3.1 | 0.0 | n/a | n/a | 0.0% |
| 2017-09-30 | 30.47 | 1.65 | 1.40p | 23.1 | 0.0 | n/a | n/a | 0.0% |
| 2018-09-30 | 0.13 | -10.15 | -7.00p | -1.2 | 0.0 | n/a | n/a | 0.0% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2019-09-30 | 0.00 | -12.64 | -0.07p | 0.0 | n/a | 0% | 0.00p | 0.0% |
| 2019-09-30 | 0.00 | -12.64 | -0.07p | 0.0 | n/a | 0% | 0.00p | 0.0% |
| 2019-09-30 | 0.00 | -12.64 | -0.07p | 0.0 | n/a | 0% | 0.00p | 0.0% |
| 2020-09-30 | 0.00 | -13.02 | -0.06p | 0.0 | n/a | 0% | 0.00p | 0.0% |
| 2020-09-30 | 0.00 | -13.02 | -0.06p | 0.0 | n/a | 0% | 0.00p | 0.0% |
| 2020-09-30 | 0.00 | -13.02 | -0.06p | 0.0 | n/a | 0% | 0.00p | 0.0% |
| Redx Pharma narrows losses as RXC004 trials recommence Sharecast News | 10 Jun |
|---|---|
| Redx Pharma extends cash runway into July Sharecast News | 03 May |
| Redx Pharma reveals promising data on 'ROCK2' compound Sharecast News | 12 Feb |
| Interim Results for six months ended 31 March 2019 | 10-Jun-19 07:06 |
|---|---|
| Short-term Debt Funding Secured | 10-Jun-19 07:03 |
| Update on Plans to Strengthen Balance Sheet | 03-May-19 11:35 |